Advertisement.

CELC Projected Dividend Yield

Celcuity Inc ( NASDAQ : CELC )

Celcuity Inc. is a clinical-stage biotechnology company developing targeted therapies for solid tumors. Its lead candidate, gedatolisib, is a small molecule inhibitor targeting all Class I PI3K isoforms and mTOR sub-complexes (mTORC1 and mTORC2). Initial clinical programs focus on treating hormone receptor positive (HR+), HER2-negative (HER2-), advanced or metastatic breast cancer, and metastatic castration-resistant prostate cancer. The VIKTORIA-1 trial evaluates gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- advanced breast cancer. The CELsignia diagnostic platform analyzes live tumor cells to identify new cancer patient groups.

21 YEAR PERFORMANCE RESULTS

CELC Dividend History Detail
CELC Dividend News
CELC Competitors News

# of Shares: 0

Closing Price: 8.85

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
2026	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000